Forrer Flavio, Rolleman Edgar, Bijster Magda, Melis Marleen, Bernard Bert, Krenning Eric P, de Jong Marion
Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
Cancer Biother Radiopharm. 2007 Feb;22(1):40-9. doi: 10.1089/cbr.2006.353.
In peptide receptor radionuclide therapy (PRRT), the dose-limiting organ is, most often, the kidney. However, the precise mechanism as well as the exact localization of kidney damage during PRRT have not been fully elucidated. We studied renal damage in rats after therapy with different amounts of [(177)Lu-DOTA(0), Tyr(3)]octreotate and investigated (99m)Tc-DMSA (dimercaptosuccinic acid) as a tool to quantify renal damage after PRRT.
Twenty-nine (29) rats were divided into 3 groups and injected with either 0, 278, or 555 MBq [(177)Lu-DOTA(0), Tyr(3) ]octreotate, leading to approximately 0, 46, and 92 Gy to the renal cortex. More than 100 days after therapy, kidney damage was investigated using (99m)Tc-DMSA single-photon emission computed tomography (SPECT) autoradiography, histology, and blood analyses.
In vivo SPECT with (99m)Tc-DMSA resulted in high-resolution (<1.6-mm) images. The (99m)Tc-DMSA uptake in the rat kidneys was inversely related with the earlier injected activity of [(177)Lu-DOTA(0), Tyr(3)]octreotate and correlated inversely with serum creatinine values. Renal ex vivo autoradiograms showed a dose-dependent distribution pattern of (99m)Tc-DMSA. (99m)Tc-DMSA SPECT could distinguish between the rats that were injected with 278 or 555 MBq [(177)Lu-DOTA(0), Tyr(3) ]octreotate, whereas histologic damage grading of the kidneys was nearly identical for these 2 groups. Histologic analyses indicated that lower amounts of injected radioactivity caused damage mainly in the proximal tubules, whereas as well the distal tubules were damaged after high-dose radioactivity.
Renal damage in rats after PRRT appeared to start in a dose-dependent manner in the proximal tubules and continued to the more distal tubules with increasing amounts of injected activity. In vivo SPECT measurement of (99m)Tc-DMSA uptake was highly accurate to grade renal tubular damage after PRRT.
在肽受体放射性核素治疗(PRRT)中,剂量限制器官通常是肾脏。然而,PRRT期间肾脏损伤的确切机制以及确切定位尚未完全阐明。我们研究了用不同剂量的[(177)Lu-DOTA(0),Tyr(3)]奥曲肽治疗后大鼠的肾脏损伤,并研究了(99m)Tc-DMSA(二巯基丁二酸)作为量化PRRT后肾脏损伤的工具。
29只大鼠分为3组,分别注射0、278或555 MBq的[(177)Lu-DOTA(0),Tyr(3)]奥曲肽,导致肾皮质接受约0、46和92 Gy的辐射。治疗100多天后,使用(99m)Tc-DMSA单光子发射计算机断层扫描(SPECT)放射自显影、组织学和血液分析来研究肾脏损伤。
(99m)Tc-DMSA的体内SPECT产生了高分辨率(<1.6毫米)图像。大鼠肾脏中(99m)Tc-DMSA的摄取与早期注射的[(177)Lu-DOTA(0),Tyr(3)]奥曲肽活性呈负相关,且与血清肌酐值呈负相关。肾脏离体放射自显影片显示了(99m)Tc-DMSA的剂量依赖性分布模式。(99m)Tc-DMSA SPECT可以区分注射278或555 MBq[(177)Lu-DOTA(0),Tyr(3)]奥曲肽的大鼠,而这两组肾脏的组织学损伤分级几乎相同。组织学分析表明,较低剂量的注入放射性主要导致近端小管损伤,而高剂量放射性后远端小管也会受损。
PRRT后大鼠的肾脏损伤似乎以剂量依赖性方式始于近端小管,并随着注入活性的增加而延伸至更远端的小管。(99m)Tc-DMSA摄取的体内SPECT测量对于PRRT后肾小管损伤分级非常准确。